Zhang Xiao-Mei, Zhou Chuanwen, Gu Huan, Yan Lu, Zhang Gui-Ying
Department of Gastroenterology, Xiangya Hospital of Central South University Changsha 410008, P. R. China.
Department of Gastroenterology, Huai'an First People's Hospital, Nanjing Medical University 6 Beijing Road West, Huai'an, 223300, China.
Int J Clin Exp Pathol. 2014 Aug 15;7(9):5902-8. eCollection 2014.
RKIP is proposed as a new metastasis suppressor. Our recent study showed that RKIP inhibits malignant phenotypes of gastric cancer cells. However, the underlying mechanism of RKIP function in gastric cancer is unclear. This study aimed to investigate the correlation of RKIP, STAT3 and cyclin D1 expression in the tumorigenesis of gastric cancer. RKIP, STAT3 and cyclin D1 proteins were detected by immunohistochemistry in tissues of gastric ulcer (n = 27), gastric adenomatous polyp (n = 7), intestinal metaplasia (n = 26), dysplasia (n = 40), gastric carcinoma (n = 169) and metastatic lymph node (n = 36). RKIP, STAT3 and cyclin D1 mRNA levels were analyzed by RT-PCR in SGC7901 cells. We found that RKIP protein expression was significantly decreased in advanced gastric cancer and metastatic lymph node tissues while cyclin D1 and STAT3 protein expression was markedly increased in severe dysplasia, gastric cancer and metastatic lymph node tissue (P < 0.01). RKIP expression in gastric cancer was negatively correlated with the invasion, TNM stage and lymphoid node metastasis (P < 0.01), while cyclin D1 and STAT3 expression was positively correlated with histological differentiation and lymphoid node metastasis (P < 0.01). RKIP protein level was negatively correlated with cyclin D1 and STAT3 protein level, while cyclin D1 protein level was positively correlated with STAT3 protein level in gastric cancer samples. Moreover, reconstitution of RKIP in SGC7901 gastric cancer cells led to reduced cyclin D1 and STAT3 mRNA levels. In conclusion, these data suggest that RKIP inhibits gastric cancer metastasis via the downregulation of its downstream target genes STAT3 and cyclin D1.
RKIP被认为是一种新的转移抑制因子。我们最近的研究表明,RKIP可抑制胃癌细胞的恶性表型。然而,RKIP在胃癌中发挥作用的潜在机制尚不清楚。本研究旨在探讨RKIP、STAT3和细胞周期蛋白D1表达在胃癌发生中的相关性。采用免疫组织化学法检测胃溃疡组织(n = 27)、胃腺瘤性息肉组织(n = 7)、肠化生组织(n = 26)、发育异常组织(n = 40)、胃癌组织(n = 169)和转移性淋巴结组织(n = 36)中RKIP、STAT3和细胞周期蛋白D1蛋白。通过RT-PCR分析SGC7901细胞中RKIP、STAT3和细胞周期蛋白D1 mRNA水平。我们发现,RKIP蛋白表达在进展期胃癌和转移性淋巴结组织中显著降低,而细胞周期蛋白D1和STAT3蛋白表达在重度发育异常、胃癌和转移性淋巴结组织中明显升高(P < 0.01)。胃癌中RKIP表达与侵袭、TNM分期和淋巴结转移呈负相关(P < 0.01),而细胞周期蛋白D1和STAT3表达与组织学分化和淋巴结转移呈正相关(P < 0.01)。在胃癌样本中,RKIP蛋白水平与细胞周期蛋白D1和STAT3蛋白水平呈负相关,而细胞周期蛋白D1蛋白水平与STAT3蛋白水平呈正相关。此外,在SGC7901胃癌细胞中重建RKIP导致细胞周期蛋白D1和STAT3 mRNA水平降低。总之,这些数据表明,RKIP通过下调其下游靶基因STAT3和细胞周期蛋白D1来抑制胃癌转移。